Bioxcel Therapeutics, Inc. (BTAI) - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held on December 12, 2025. The filing covers the voting outcomes for five proposals presented to shareholders. As of the record date (October 31, 2025), approximately 44.68% of outstanding common stock was represented at the meeting.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The following proposals were voted upon and approved:
- Proposal 1 (Director Election): Three Class I directors were elected for a term expiring in 2028.
- June Bray: 1,735,749 votes FOR; 322,163 votes WITHHELD.
- Sandeep Laumas, M.D.: 1,474,122 votes FOR; 583,790 votes WITHHELD.
- David Mack: 1,840,490 votes FOR; 217,422 votes WITHHELD.
- Proposal 2 (Auditor Ratification): Ratification of Ernst & Young LLP as independent registered public accounting firm.
- Result: 9,478,711 votes FOR; 202,558 votes AGAINST; 45,580 votes ABSTAINED.
- Proposal 3 (Executive Compensation): Advisory approval of named executive officer compensation.
- Result: 1,616,305 votes FOR; 394,890 votes AGAINST; 46,717 votes ABSTAINED.
- Proposal 4 (Reverse Stock Split Authorization): Approval to amend the Certificate of Incorporation to effect a reverse stock split (ratio 1-for-2 to 1-for-20) if necessary to regain compliance with Nasdaq Capital Market minimum bid price requirements.
- Result: 7,557,091 votes FOR; 2,116,237 votes AGAINST; 53,521 votes ABSTAINED.
- Proposal 5 (Adjournment Authorization): Authorization to adjourn the meeting to solicit additional proxies if Proposal 4 failed.
- Result: 8,137,303 votes FOR; 1,508,591 votes AGAINST; 80,955 votes ABSTAINED.
Adjournment was deemed unnecessary as Proposal 4 received sufficient votes for approval.
Guidance, Outlook, and Risks
The filing indicates a specific risk regarding compliance with the Nasdaq Capital Market minimum bid price requirements. The approval of Proposal 4 grants the Board the authority to execute a reverse stock split within 12 months if the Board determines it is necessary and advisable to regain compliance. No other forward-looking guidance or financial outlook is provided in this text.
Investor Verification Checklist
- Verify the current trading price of BTAI to assess the immediate necessity of the authorized reverse stock split.
- Review the definitive Proxy Statement (Schedule 14A) filed on November 12, 2025, for detailed biographies of the elected directors and executive compensation specifics.
- Monitor future Board announcements regarding the specific ratio and timing of any potential reverse stock split.
- Check subsequent filings (10-K or 10-Q) for the company's actual financial position, as this 8-K contains no financial data.